Literature DB >> 17180681

Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

T Rodríguez1, R Méndez, A Del Campo, N Aptsiauri, J Martín, G Orozco, G Pawelec, D Schadendorf, F Ruiz-Cabello, F Garrido.   

Abstract

Major histocompatibility complex (MHC) class II proteins (HLA-DR, HLA-DP and HLA-DQ) play a fundamental role in the regulation of the immune response. The level of expression of human leukocyte antigen (HLA) class II antigens is regulated by interferon-gamma (IFN-gamma) and depends on the status of class II trans-activator protein (CIITA), a co-activator of the MHC class II gene promoter. In this study, we measured levels of constitutive and IFN-gamma-induced expression of MHC class II molecules, analysed the expression of CIITA and investigated the association between MHC class II transactivator polymorphism and expression of different MHC class II molecules in a large panel of melanoma cell lines obtained from the European Searchable Tumour Cell Line Database. Many cell lines showed no constitutive expression of HLA-DP, HLA-DQ and HLA-DR and no IFN-gamma-induced increase in HLA class II surface expression. However, in some cases, IFN-gamma treatment led to enhanced surface expression of HLA-DP and HLA-DR. HLA-DQ was less frequently expressed under basal conditions and was less frequently induced by IFN-gamma. In these melanoma cell lines, constitutive surface expression of HLA-DR and HLA-DP was higher than that of HLA-DQ. In addition, high constitutive level of cell surface expression of HLA-DR was correlated with lower inducibility of this expression by IFN-gamma. Finally, substitution A-->G in the 5' flanking region of CIITA promoter type III was associated with higher expression of constitutive HLA-DR (p<0.005). This study yielded a panel of melanoma cell lines with different patterns of constitutive and IFN-gamma-induced expression of HLA class II that can be used in future studies of the mechanisms of regulation of HLA class II expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17180681     DOI: 10.1007/s00251-006-0171-9

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  52 in total

1.  Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines.

Authors:  Nienke van der Stoep; Paula Biesta; Edwin Quinten; Peter J van den Elsen
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

2.  Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1.

Authors:  A Muhlethaler-Mottet; W Di Berardino; L A Otten; B Mach
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

3.  Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.

Authors:  D E Elder; U Rodeck; J Thurin; F Cardillo; W H Clark; R Stewart; M Herlyn
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

4.  CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame.

Authors:  Elisabeth H Slager; Martina Borghi; Carolien E van der Minne; Corlien A Aarnoudse; Menzo J E Havenga; Peter I Schrier; Susanne Osanto; Marieke Griffioen
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

5.  Phenotypic dynamics of tumor progression in human malignant melanoma.

Authors:  E B Bröcker; L Suter; J Brüggen; D J Ruiter; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

6.  Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta.

Authors:  J F Piskurich; M W Linhoff; Y Wang; J P Ting
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

7.  Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.

Authors:  Ayumi Satoh; Minoru Toyota; Hideyuki Ikeda; Yoshikazu Morimoto; Kimishige Akino; Hiroaki Mita; Hiromu Suzuki; Yasushi Sasaki; Takayuki Kanaseki; Yukio Takamura; Hidenobu Soejima; Takeshi Urano; Kazuyoshi Yanagihara; Takao Endo; Yuji Hinoda; Masahiro Fujita; Masao Hosokawa; Noriyuki Sato; Takashi Tokino; Kohzoh Imai
Journal:  Oncogene       Date:  2004-11-25       Impact factor: 9.867

8.  Modulation of gene expression by the MHC class II transactivator.

Authors:  Uma M Nagarajan; Alyssa Bushey; Jeremy M Boss
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

9.  DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization.

Authors:  B S Wilson; F Indiveri; M A Pellegrino; S Ferrone
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

10.  Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.

Authors:  Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Jan Mueller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

View more
  10 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 2.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

3.  Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.

Authors:  Dan Zhao; Shereen Amria; Azim Hossain; Kumaran Sundaram; Peter Komlosi; Mitzi Nagarkatti; Azizul Haque
Journal:  Cell Immunol       Date:  2011-08-18       Impact factor: 4.868

4.  Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.

Authors:  Annedore Respa; Juergen Bukur; Soldano Ferrone; Graham Pawelec; Yingdong Zhao; Ena Wang; Francesco M Marincola; Barbara Seliger
Journal:  Clin Cancer Res       Date:  2011-01-19       Impact factor: 12.531

5.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

6.  EBP1 and DRBP76/NF90 binding proteins are included in the major histocompatibility complex class II RNA operon.

Authors:  Carmela Corso; Laura Pisapia; Alessandra Citro; Valeria Cicatiello; Pasquale Barba; Luisa Cigliano; Paolo Abrescia; Antonella Maffei; Giuseppe Manco; Giovanna Del Pozzo
Journal:  Nucleic Acids Res       Date:  2011-05-29       Impact factor: 16.971

7.  Interferon Gamma +874T/A Polymorphism Increases the Risk of Hepatitis Virus-Related Diseases: Evidence from a Meta-Analysis.

Authors:  Yifan Sun; Yu Lu; Taijie Li; Li Xie; Yan Deng; Shan Li; Xue Qin
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

Review 8.  IFN inducibility of major histocompatibility antigens in tumors.

Authors:  Barbara Seliger; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

9.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Authors:  Douglas B Johnson; Monica V Estrada; Roberto Salgado; Violeta Sanchez; Deon B Doxie; Susan R Opalenik; Anna E Vilgelm; Emily Feld; Adam S Johnson; Allison R Greenplate; Melinda E Sanders; Christine M Lovly; Dennie T Frederick; Mark C Kelley; Ann Richmond; Jonathan M Irish; Yu Shyr; Ryan J Sullivan; Igor Puzanov; Jeffrey A Sosman; Justin M Balko
Journal:  Nat Commun       Date:  2016-01-29       Impact factor: 14.919

10.  Functional disruption of human leukocyte antigen II in human embryonic stem cell.

Authors:  Haide Chen; Yang Li; Xijuan Lin; Di Cui; Chun Cui; Hui Li; Lei Xiao
Journal:  Biol Res       Date:  2015-10-27       Impact factor: 5.612

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.